89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class

 
• By Joseph Haas
  
Two racers
Competition between 89bio and Akero in NASH is tightening • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D